SEHK:1801Biotechs
How Investors May Respond To Innovent Biologics (SEHK:1801) Advancing Oral And Extended-Interval GLP-1 Candidates
In early June 2026, Innovent Biologics presented new clinical and preclinical data across its obesity and metabolic pipeline at the American Diabetes Association Scientific Sessions, including first-in-human results for its oral GLP-1 receptor agonist IBI3032 and updates on mazdutide and other next-generation candidates.
A distinctive angle for investors is Innovent’s push into true oral and once-weekly small-molecule GLP-1 therapies, aiming to combine low-dose efficacy with improved...